236 related articles for article (PubMed ID: 28810819)
1. Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34
Wang YY; Chen WL; Weng XQ; Sheng Y; Wu J; Hao J; Liu ZY; Zhu YM; Chen B; Xiong SM; Chen Y; Chen QS; Sun HP; Li JM; Wang J
Stem Cells Dev; 2017 Oct; 26(20):1460-1467. PubMed ID: 28810819
[TBL] [Abstract][Full Text] [Related]
2. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
3. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
van Rhenen A; van Dongen GA; Kelder A; Rombouts EJ; Feller N; Moshaver B; Stigter-van Walsum M; Zweegman S; Ossenkoppele GJ; Jan Schuurhuis G
Blood; 2007 Oct; 110(7):2659-66. PubMed ID: 17609428
[TBL] [Abstract][Full Text] [Related]
4. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
6. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
[TBL] [Abstract][Full Text] [Related]
7. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.
Damiani D; Tiribelli M; Raspadori D; Sirianni S; Meneghel A; Cavalllin M; Michelutti A; Toffoletti E; Geromin A; Simeone E; Bocchia M; Fanin R
Oncotarget; 2015 Oct; 6(30):30212-21. PubMed ID: 26338961
[TBL] [Abstract][Full Text] [Related]
9. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of CD56 Antigen Expression in Patients with
Sun Y; Wan J; Song Q; Luo C; Li X; Luo Y; Huang X; Ding R; Li H; Hou Y; Huang Y; Xie M; Huang Z; Zhang Y; Ma Y; Wu G; Xu S; Chen J
Biomed Res Int; 2021; 2021():1929357. PubMed ID: 33928145
[TBL] [Abstract][Full Text] [Related]
11. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
12. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
Bakker AB; van den Oudenrijn S; Bakker AQ; Feller N; van Meijer M; Bia JA; Jongeneelen MA; Visser TJ; Bijl N; Geuijen CA; Marissen WE; Radosevic K; Throsby M; Schuurhuis GJ; Ossenkoppele GJ; de Kruif J; Goudsmit J; Kruisbeek AM
Cancer Res; 2004 Nov; 64(22):8443-50. PubMed ID: 15548716
[TBL] [Abstract][Full Text] [Related]
13. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
15. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
[TBL] [Abstract][Full Text] [Related]
16. C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study.
Wang J; Wang W; Chen H; Li W; Huang T; Zhang W; Ling W; Lai P; Wang Y; Geng S; Li M; Du X; Weng J
Biomed Res Int; 2021; 2021():6643948. PubMed ID: 33778076
[TBL] [Abstract][Full Text] [Related]
17. Human myeloid inhibitory C-lectin: a highly specific and stable acute myeloid leukemia marker.
Eissa DS; Kandeel EZ; Ghareeb M
Hematol Oncol; 2017 Dec; 35(4):814-820. PubMed ID: 27734526
[TBL] [Abstract][Full Text] [Related]
18. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
19. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML.
Sperling C; Büchner T; Creutzig U; Ritter J; Harbott J; Fonatsch C; Sauerland C; Mielcarek M; Maschmeyer G; Löffler H
Leuk Lymphoma; 1995 May; 17(5-6):417-26. PubMed ID: 7549832
[TBL] [Abstract][Full Text] [Related]
20. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
